ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in AUPH — Aurinia Pharmaceuticals Inc.
CIK 1164508
BOSTON, MA
Position in AUPH
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$55,391,132
+$6,716,799 QoQ
Shares Held
3,264,062
-0.6% QoQ
Ownership
2.45%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#6
of 279 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AUPH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $2,519,535,758 across 72 Biotechnology names. AUPH ranks #10 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
738,378 | $366,774,503 | |
| 2 | INCY |
Incyte Corp
|
2,744,958 | $311,168,438 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
393,685 | $245,478,344 | |
| 4 | EXEL |
Exelixis, Inc.
|
4,365,926 | $237,550,033 | |
| 5 | GMAB |
Genmab A/S
|
4,975,324 | $136,672,150 | |
| 6 | RPRX |
Royalty Pharma plc
|
2,435,341 | $136,549,569 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
1,704,623 | $133,420,842 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
249,758 | $71,173,537 |
All Filings in AUPH
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $55,391,132 | 3,264,062 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $48,674,333 | 3,284,368 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $54,025,744 | 3,387,194 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $37,282,932 | 3,374,021 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $9,114,719 | 1,076,118 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $13,189,073 | 1,640,432 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $9,661,680 | 1,075,911 | Shares | Defined | 2025-02-12 | |
| No filing history on record for this holder in this stock. | ||||||